JPWO2024034591A5 - - Google Patents

Info

Publication number
JPWO2024034591A5
JPWO2024034591A5 JP2024540479A JP2024540479A JPWO2024034591A5 JP WO2024034591 A5 JPWO2024034591 A5 JP WO2024034591A5 JP 2024540479 A JP2024540479 A JP 2024540479A JP 2024540479 A JP2024540479 A JP 2024540479A JP WO2024034591 A5 JPWO2024034591 A5 JP WO2024034591A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
group
alkylene
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540479A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024034591A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/028860 external-priority patent/WO2024034591A1/ja
Publication of JPWO2024034591A1 publication Critical patent/JPWO2024034591A1/ja
Publication of JPWO2024034591A5 publication Critical patent/JPWO2024034591A5/ja
Pending legal-status Critical Current

Links

JP2024540479A 2022-08-09 2023-08-08 Pending JPWO2024034591A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022126817 2022-08-09
PCT/JP2023/028860 WO2024034591A1 (ja) 2022-08-09 2023-08-08 Krasタンパクを阻害及び/又は分解誘導するための複素環化合物

Publications (2)

Publication Number Publication Date
JPWO2024034591A1 JPWO2024034591A1 (cg-RX-API-DMAC7.html) 2024-02-15
JPWO2024034591A5 true JPWO2024034591A5 (cg-RX-API-DMAC7.html) 2026-02-18

Family

ID=89851832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540479A Pending JPWO2024034591A1 (cg-RX-API-DMAC7.html) 2022-08-09 2023-08-08

Country Status (6)

Country Link
US (1) US20250388569A1 (cg-RX-API-DMAC7.html)
EP (1) EP4570794A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024034591A1 (cg-RX-API-DMAC7.html)
CN (1) CN119768398A (cg-RX-API-DMAC7.html)
TW (1) TW202412790A (cg-RX-API-DMAC7.html)
WO (1) WO2024034591A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202545934A (zh) * 2024-02-05 2025-12-01 日商安斯泰來製藥股份有限公司 包含具有突變kras蛋白分解誘導作用之雜環化合物的抗體藥物複合體
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
TW202124374A (zh) 2019-09-13 2021-07-01 美商拜歐斯瑞克斯公司 Ras蛋白降解劑、其醫藥組合物及其治療應用
US20220370416A1 (en) 2020-04-06 2022-11-24 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2022002102A1 (en) 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
CA3195457A1 (en) 2020-10-14 2022-04-21 Weiwen Ying Methods and compositions for targeted protein degradation
AU2021362975A1 (en) 2020-10-14 2023-05-25 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
US20240092803A1 (en) 2021-01-08 2024-03-21 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022148422A1 (en) 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
LT4293024T (lt) 2021-02-15 2026-05-25 Astellas Pharma Inc. Chinazolino junginys, skirtas g12d mutantinio kras baltymo degradacijai sukelti
CN115260158A (zh) 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
WO2023280026A1 (zh) 2021-07-05 2023-01-12 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途
CN115785199A (zh) 2021-09-10 2023-03-14 润佳(苏州)医药科技有限公司 一种双官能化合物及其用途
WO2023077441A1 (en) 2021-11-05 2023-05-11 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation

Similar Documents

Publication Publication Date Title
IL307443A (en) A short ring-modified peptide compound of proline and its use
JP2006500370A5 (cg-RX-API-DMAC7.html)
AR040806A1 (es) Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento
SE7701045L (sv) Prostansyraderivat
JP2005505618A5 (cg-RX-API-DMAC7.html)
NO167920C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive tricykliske 1,4-azepinderivater
CA2164303A1 (en) Aromatic Acetylcholinesterase Inhibitors
ATE2519T1 (de) N-phenoxyalkylpiperidin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
JPS6479153A (en) Novel pyridyl compound
RU2003121308A (ru) 3,7-диазабицикло[3.3.0]октаны и их применение при лечении сердечных аритмий
DE69432542D1 (de) Tetraderivate, ihre Herstellung und Verwendung
ATE304014T1 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates
SE7705423L (sv) Forfarande for framstellning av prostaglandinderivat
ATE170859T1 (de) Antibiotische carbapenemverbindungen
PT74199A (de) Neue trisubstituierte pyrimido<5,4-d>pyrimidine ihre herstel- lung und ihre verwendung als arzneimittel
ES2077777T3 (es) Derivado del acido naftoico.
ATE5145T1 (de) O-creatinolphosphatderivat mit therapeutischer wirkung, verfahren zu dessen herstellung und dessen pharmazeutische zusammensetzungen.
JPS5283396A (en) Novel compound physiologically acceptable salts thereof process for preparing same and medical composition containing same
DE3881164D1 (de) Verwendung eines tetrahydro-pyrido(2,3-d)pyrimidins zur herstellung eines analgetikums.
AR044343A1 (es) Derivados de diarilmetilidenopiperidina, preparaciones de los mismos y usos de los mismos
ATE170860T1 (de) Antibiotische carbapenemverbindungen
SE8005560L (sv) Nya, hologenerade 15-hydroxi-e-homoeburnanderivat jemte sett for deras framstellning
RU2020113587A (ru) Тиенодиазепиновые производные и их применение
RU2025134685A (ru) ИНГИБИТОРЫ GSK3α И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2004125289A (ru) Способ получения производных морфолина и их промежуточных соединений